Ian A. Critchley
Corporate Officer/Principal bei SPERO THERAPEUTICS, INC.
Aktive Positionen von Ian A. Critchley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SPERO THERAPEUTICS, INC. | Corporate Officer/Principal | 01.04.2018 | - |
Karriereverlauf von Ian A. Critchley
Ehemalige bekannte Positionen von Ian A. Critchley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ALLERGAN PLC | Corporate Officer/Principal | 01.01.2015 | 01.04.2018 |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Corporate Officer/Principal | 01.06.2008 | 01.12.2014 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Corporate Officer/Principal | 01.11.2002 | 01.06.2008 |
Ausbildung von Ian A. Critchley
University of Glasgow | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Vereinigtes Königreich | 2 |
Irland | 2 |
Operativ
Corporate Officer/Principal | 4 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SPERO THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Allergan Ltd. (Ireland)
Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Health Technology |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Health Technology |
- Börse
- Insiders
- Ian A. Critchley
- Erfahrung